714 reports of this reaction
5.7% of all LORATADINE AND PSEUDOEPHEDRINE SULFATE reports
#2 most reported adverse reaction
INSOMNIA is the #2 most commonly reported adverse reaction for LORATADINE AND PSEUDOEPHEDRINE SULFATE, manufactured by Bayer HealthCare LLC.. There are 714 FDA adverse event reports linking LORATADINE AND PSEUDOEPHEDRINE SULFATE to INSOMNIA. This represents approximately 5.7% of all 12,600 adverse event reports for this drug.
Patients taking LORATADINE AND PSEUDOEPHEDRINE SULFATE who experience insomnia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INSOMNIA is moderately reported among LORATADINE AND PSEUDOEPHEDRINE SULFATE users, representing a notable but not dominant share of adverse events.
In addition to insomnia, the following adverse reactions have been reported for LORATADINE AND PSEUDOEPHEDRINE SULFATE:
The following drugs have also been linked to insomnia in FDA adverse event reports:
INSOMNIA has been reported as an adverse event in 714 FDA reports for LORATADINE AND PSEUDOEPHEDRINE SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INSOMNIA accounts for approximately 5.7% of all adverse event reports for LORATADINE AND PSEUDOEPHEDRINE SULFATE, making it one of the most commonly reported side effect.
If you experience insomnia while taking LORATADINE AND PSEUDOEPHEDRINE SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.